CStone Pharmaceuticals (02616.HK)株価、チャート、ニュース、およびAI分析

Q: CStone Pharmaceuticals のCEOは誰ですか？

Dr. Jianxin Yang は CStone Pharmaceuticals の Chief Executive Officer で、2016 から在籍しています。

Q: CSTONE PHARMA-B の株価パフォーマンスは？

CSTONE PHARMA-B の現在の価格は $6.11 で、最終取引日から 4.53% 減少 変動しました。

Q: CStone Pharmaceuticals の主な事業テーマや業界は？

CStone Pharmaceuticals は Biotechnology 業界、セクターは Health Care に属しています。

Q: CStone Pharmaceuticals の時価総額はいくらですか？

CStone Pharmaceuticals の現在の時価総額は $8.9B です。

ホーム

株式

02616.HK

CSTONE PHARMA-B (02616.HK)

CStone Pharmaceuticals

HK$6.11

-4.53%

$-0.29

休場: Jan 16, 16:00:00 HKT

主要データ

前終値

$6.32

始値

$6.4

当日レンジ

$6.08 - $6.4

52週レンジ

$2.02 - $13.15

取引高

3.4M

平均取引高

10.9M

1株当たり利益(TTM)

-0.32

配当利回り

時価総額

$8.9B

CSTONE PHARMA-Bとは何ですか？

Cstone Pharmaceuticals Co. Ltd. is an investment holding company, which engages in the research and development of complex biopharmaceutical products and sale of pharmaceutical products. The company is headquartered in Suzhou, Jiangsu and currently employs 93 full-time employees. The company went IPO on 2019-02-26. Through its subsidiaries, the Company is primarily engaged in the research and development of biopharmaceutical products, the sales of pharmaceutical products, as well as the provision of license of its intellectual property (IP) or commercialization license. The Company’s products primarily include targeted therapies, AYVAKIT (avapritinib), GAVRETO (pralsetinib) and CEJEMLY (sugemalimab). The firm is also engaged in the development and commercialization of immuno-oncology. The firm primarily conducts its businesses in the domestic market and overseas markets, such as Central and Eastern Europe and Switzerland.

特徴

取引戦略